D. Goldsmith

发表

Neural Correlates of Social Cooperation and Non-Cooperation as a Function of Psychopathy

G. Pagnoni, J. Rilling, A. Glenn, 2007, Biological Psychiatry.

A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression

D. Goldsmith, B. Miller, M. Rapaport, 2016, Molecular Psychiatry.

The neural correlates of the affective response to unreciprocated cooperation

G. Pagnoni, J. Rilling, A. Glenn, 2008, Neuropsychologia.

Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression

Zhihao Li, D. Goldsmith, N. Le, 2020, Brain, Behavior, and Immunity.

Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for Conversion

E. Walker, D. Goldsmith, Justin K. Ellis, 2020, Frontiers in Psychiatry.

Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology

D. Goldsmith, B. Miller, 2019 .

Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia

M. Treadway, D. Goldsmith, Andrew H. Miller, 2020, Brain, Behavior, and Immunity.

Where there’s smoke, there’s fire: Cannabis, P2RX7 and inflammatory pathways intersect to increase psychosis susceptibility

D. Goldsmith, 2020, Brain, Behavior, and Immunity.

Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions

D. Goldsmith, B. Miller, 2017, Neuropsychopharmacology.

Mammalian Cell-Derived Somatropin

D. Goldsmith, A. Wagstaff, 2012, Drugs.

Doxazosin Gastrointestinal Therapeutic System

D. Goldsmith, G. Plosker, 2012, Drugs.

Spotlight on Lamotrigine in Bipolar Disorder

C. Perry, D. Goldsmith, A. Wagstaff, 2004, CNS Drugs.

Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?

M. Pompili, D. Lamis, D. Goldsmith, 2017, CNS & neurological disorders drug targets.

Budesonide/Formoterol

D. Goldsmith, G. Keating, 2012, Drugs.

Sevelamer Hydrochloride

D. Goldsmith, Risto S. Cvetković, G. Plosker, 2008, Drugs.

Naftidrofuryl: a review of its use in the treatment of intermittent claudication.

D. Goldsmith, K. Wellington, 2005, Drugs & aging.

Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

D. Goldsmith, Benjamin J Kahn, Mina Boazak, 2018, Clinical schizophrenia & related psychoses.

Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic

D. Goldsmith, Catherine W Bennett, Lauren Gensler, 2022, Community Mental Health Journal.

The interaction of lipids and inflammatory markers predict negative symptom severity in patients with schizophrenia

D. Goldsmith, Erica Duncan, Andrew H. Miller, 2021, npj Schizophrenia.

A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists

D. Goldsmith, Beth Broussard, Yunshen Jiao, 2021, Community Mental Health Journal.

Parental type 2 diabetes in patients with non-affective psychosis

D. Goldsmith, P. Buckley, B. Miller, 2016, Schizophrenia Research.

Donepezil: in vascular dementia.

D. Goldsmith, L. Scott, 2003, Drugs & aging.

Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

D. Goldsmith, B. Miller, 2020, Focus.

Toxoplasma gondii Effects on the Relationship of Kynurenine Pathway Metabolites to Acoustic Startle Latency in Schizophrenia vs. Control Subjects

B. Cuthbert, D. Goldsmith, D. Barr, 2020, Frontiers in Psychiatry.

Lamotrigine: a review of its use in bipolar disorder.

C. Perry, D. Goldsmith, A. Wagstaff, 2003, Drugs.

Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications

M. Treadway, D. Goldsmith, Andrew H. Miller, 2021, Pharmacological Reviews.

Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder

D. Goldsmith, Andrew H. Miller, E. Haroon, 2018, Psychoneuroendocrinology.

What does plasma CRP tell us about peripheral and central inflammation in depression?

D. Goldsmith, M. Tansey, Andrew H. Miller, 2018, Molecular Psychiatry.

Brick by Brick: Building a Transdiagnostic Understanding of Inflammation in Psychiatry.

D. Goldsmith, David S. Thylur, 2022, Harvard review of psychiatry.

Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls

B. Cuthbert, D. Goldsmith, Erica Duncan, 2020, npj Schizophrenia.

Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits

D. Goldsmith, M. Rapaport, 2020, Frontiers in Psychiatry.

Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis

D. Mathalon, T. McGlashan, E. Walker, 2019, Brain, Behavior, and Immunity.

TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia

D. Goldsmith, P. Buckley, Andrew H. Miller, 2018, Schizophrenia Research.

The Immunology of Behavior ‖ Towards an Immunophenotype of Schizophrenia : Progress , Potential Mechanisms , and Future Directions Running Title : Schizophrenia Immunophenotype

D. Goldsmith, B. Miller, 2016 .

Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic

D. Goldsmith, B. Miller, Anna Zimmer, 2020, Brain, Behavior, and Immunity.

Transcriptomic Signatures of Psychomotor Slowing in Peripheral Blood of Depressed Patients: Evidence for Immunometabolic Reprogramming

D. Goldsmith, Andrew H. Miller, E. Haroon, 2021, Molecular Psychiatry.

Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder

Philip D. Harvey, M. Treadway, D. Goldsmith, 2016, Brain, Behavior, and Immunity.

Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky.

D. Goldsmith, Mina Boazak, Robert O. Cotes, 2018, The primary care companion for CNS disorders.

An Update on Promising Biomarkers in Schizophrenia.

E. Walker, D. Goldsmith, Robert O. Cotes, 2018, Focus.

Spotlight on Mammalian Cell-Derived Somatropin in HIV-Associated Wasting

D. Goldsmith, A. Wagstaff, 2012, BioDrugs.

Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review

J. Turner, D. Goldsmith, K. Rootes-Murdy, 2022, Frontiers in Integrative Neuroscience.

Cluster Analysis of Clozapine Consumer Perspectives and Comparison to Consumers on Other Antipsychotics

D. Goldsmith, Beth Broussard, Robert O. Cotes, 2021, Schizophrenia bulletin open.

Schizophrenia: A scientific graveyard or a pragmatically useful diagnostic construct?

E. Walker, D. Goldsmith, 2022, Schizophrenia Research.

Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis.

D. Goldsmith, A. Wagstaff, 2005, American journal of clinical dermatology.

Etanercept of its Use in the Management of Plaque Psoriasis and

D. Goldsmith, A. Wagstaff, A. Evaluation, 2005 .

Inhaled Iloprost

D. Goldsmith, A. Wagstaff, 2012, Drugs.

Amphotericin B lipid complex: in visceral leishmaniasis.

C. Perry, D. Goldsmith, 2004, Drugs.

Social cognitive neural networks during in-group and out-group interactions

Giuseppe Pagnoni, James K. Rilling, Andrea L. Glenn, 2008, NeuroImage.

The human lncRNA GOMAFU suppresses neuronal interferon response pathways affected in neuropsychiatric diseases

D. Goldsmith, Yue Feng, Z. Wen, 2023, Brain, Behavior, and Immunity.

Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression

D. Goldsmith, Andrew H. Miller, E. Haroon, 2020, Neuropsychopharmacology.

Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy

B. Druss, D. Goldsmith, Robert O. Cotes, 2018, Community Mental Health Journal.

Integrating Diversity, Equity, and Inclusion Into an Academic Department of Psychiatry and Behavioral Sciences.

D. Goldsmith, N. Kaslow, N. Fani, 2021, Focus.

Psychosis as an adverse effect of monoclonal antibody immunotherapy

D. Goldsmith, B. Miller, Norah Essali, 2019, Brain, Behavior, and Immunity.

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

D. Goldsmith, Risto S. Cvetković, G. Plosker, 2008, Drugs.

Spotlight on Etanercept in Plaque Psoriasis and Psoriatic Arthritis

D. Goldsmith, A. Wagstaff, 2012, BioDrugs.

Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary

D. Goldsmith, B. Miller, A. Chandra, 2023, Brain, Behavior, and Immunity.

Social cognitive neural networks during in-group and out-group interactions

G. Pagnoni, J. Rilling, A. Glenn, 2008, NeuroImage.

Integration of Clozapine-associated Harm Obsessions into Cognitive Behavioral Conceptualization and Treatment Planning for Thought Broadcasting: A Case Study

D. Goldsmith, Robert O. Cotes, S. Kopelovich, 2020, Journal of psychiatric practice.